World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Case Report

Volume 14, Number 6, December 2023, pages 575-579

Dramatic Improvement of Pulmonary Tumor Thrombotic Microangiopathy in a Breast Cancer Patient Treated With Bevacizumab

Figures

Figure 1.
Figure 1. Positron emission tomography showing multiple lymph nodes and bone and liver metastasis.
Figure 2.
Figure 2. Pulmonary perfusion scintigraphy showing multiple non-segmental defects.
Figure 3.
Figure 3. Computed tomography scan showing multiple infiltrations in both lungs (yellow arrows) 2 days after the start of chemotherapy.

Table

Table 1. Cases of PTTM Treated With Bevacizumab
 
AuthorYearAgePrimary diseaseTreatmentPrognosis
PTTM: pulmonary tumor thrombotic microangiopathy; CDDP: cisplatin; Bev: bevacizumab; nab-PTX: albumin paclitaxel.
Taniguchi et al [8]202166UterineCDDP + PTX + Bev> 6 months
Higo et al [9]201461ColorectalImatinib + CDDP + Bev + S-112 months
Lu et al [10]202151LungNab-PTX + nedaplatin + Bev21 days
Current case47BreastPTX + Bev1 year and 8 months